Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)

Genome editing for the treatment of human disease (GenE-HumDi) is an EU-funded COST Action for the development and consolidation of academic, industrial and healthcare feedback networks aiming to accelerate, foster and harmonize the approval of genome-editing (GE) therapies. GenE-HumDi offers mobility grants, supports educational courses, and hosts conferences and meetings to promote synergistic interactions among and across partners active in the discovery, validation, optimization, manufacturing and clinical application of genomic medicines. Furthermore, it provides young and early career scientists with a supportive and world-class environment to foster networking and international collaborations within the GE field. We compiled the proceedings of the second Annual GenE-HumDi Meeting held in Limassol, Cyprus, in 2024. Over three days, renowned experts from the field updated an audience of over 70 GenE-HumDi members and non-member scientists on the latest discoveries and ongoing projects, discussed the status of the field, and identified GenE-HumDi action priorities to advance research and development for GE medicines. Seven focused discussion groups identified gaps in knowledge, standardization and dissemination for new GE tools, delivery methods, safety monitoring, validation for clinical use, and progress in industrial manufacturing and regulatory issues. Simultaneously, publicity about the event itself contributed to outreach and dissemination of GE for human diseases. Therefore, the conclusions of that meeting, summarized here, serve as a compass toward GE application in Europe through coordination, enhanced collaboration and focus on critical developments.

Authors

Institutions

Publication Details

Journal
Frontiers in Genome Editing
Published
2025-11-03
DOI
https://doi.org/10.3389/fgeed.2025.1667329
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)

Juan R. Rodríguez-Madoz, Alessia Cavazza, Karim Benabdellah, Yonglun Luo et al.
Frontiers in Genome Editing
CRISPR and Genetic Engineering
article

Proceedings of the second annual meeting of GenE-HumDi (COST Action 21113)

Juan R. Rodríguez-Madoz, Alessia Cavazza, Karim Benabdellah, Yonglun Luo, Claudio Mussolino, Oliver Feeney, Petros Patsali, Francisco J. Molina-Estévez, Iris Ramos-Hernández, Lluı́s Montoliu, Ayal Hendel, Nechama Kalter, Carsten W. Lederer, Rajesh Ramachandran Nair, María Ortiz-Bueno, Merita Xhetani, Luis Algeciras-Jiménez, Jose Bonafont, Laura Torella
article en

Abstract

Genome editing for the treatment of human disease (GenE-HumDi) is an EU-funded COST Action for the development and consolidation of academic, industrial and healthcare feedback networks aiming to accelerate, foster and harmonize the approval of genome-editing (GE) therapies. GenE-HumDi offers mobility grants, supports educational courses, and hosts conferences and meetings to promote synergistic interactions among and across partners active in the discovery, validation, optimization, manufacturing and clinical application of genomic medicines. Furthermore, it provides young and early career scientists with a supportive and world-class environment to foster networking and international collaborations within the GE field. We compiled the proceedings of the second Annual GenE-HumDi Meeting held in Limassol, Cyprus, in 2024. Over three days, renowned experts from the field updated an audience of over 70 GenE-HumDi members and non-member scientists on the latest discoveries and ongoing projects, discussed the status of the field, and identified GenE-HumDi action priorities to advance research and development for GE medicines. Seven focused discussion groups identified gaps in knowledge, standardization and dissemination for new GE tools, delivery methods, safety monitoring, validation for clinical use, and progress in industrial manufacturing and regulatory issues. Simultaneously, publicity about the event itself contributed to outreach and dissemination of GE for human diseases. Therefore, the conclusions of that meeting, summarized here, serve as a compass toward GE application in Europe through coordination, enhanced collaboration and focus on critical developments.

Frontiers in Genome EditingVol. 7
University of Modena and Reggio Emilia (IT), Steno Diabetes Centers (DK), Bar-Ilan University (IL), University of Freiburg (DE), Aarhus University (DK), Great Ormond Street Hospital (GB), University Medical Center Freiburg (DE), Instituto de Salud Carlos III (ES), Aarhus University Hospital (DK), Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (ES), Centro Nacional de Biotecnología (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Navarre Institute of Health Research (ES), Centro de Investigación Biomédica en Red (ES), Clinica Universidad de Navarra (ES), Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (ES), Technical Services and Supplies (Spain) (ES), Kavli Institute for Systems Neuroscience (NO), University College London (GB), Cyprus Institute of Neurology and Genetics (CY), University of Tirana (AL), University of Tübingen (DE), Universidad de Navarra (ES)
Openalex Percentile: Top 72%
CRISPR and Genetic Engineering
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.